Opyl Ltd (opl) Logo

Opyl Ltd (OPL)

___:___ · AUD
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

OPL Chart

OPL's Principal Activity is the continued development of its digital tools that improve the healthcare experience for patients, deliver market insights from social media data and improve the efficiency and value of clinical research process.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) +26.29%
vs ASX 200 (1yr) +28.67%

Size

Market Capitalisation
ASX Rank 2,068 of 2,295
Sector Rank 175 of 204

Key Information

Shares Issued
Sector Technology
Similar Companies SIS / TGO / TCN
EPS $0.058
DPS $0.00
NTA per share $0.02

Broker Consensus

OPL is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Company Overview

Opyl Limited (OPL, formerly ShareRoot Ltd) provides biopharma and health organisations access to emerging AI-assisted technologies and professional guidance to understand and improve healthcare design, development and delivery.

Incorporation Details

Incorporated in QLD on 15/01/1994. Changed its status from NL to Ltd on 21/02/2003.

Corporate Details

Head Office St Kilda VIC 3182
Website www.opyl.ai
Registry Automic Group
Auditor William Buck Audit (VIC) Pty Ltd
Date Listed 7 Mar 1996

Upcoming Calendar (Forecasted)

Date Event
27/08/2021 Report (Prelim)
27/08/2021 Report (Annual)
27/10/2021 Report (Annual)
24/02/2022 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Dr Megan Robertson Non-Executive Director May 2021 Director Bio icon

Dr Megan Robertson

Non-Executive Director

Dr Robertson has clinical and commercial experience and knowledge in the health sector. She is the current Group Chief Research Officer at St Vincent's Health Australia and Director of Research at St Vincent's Hospital, Melbourne. She also works as a Senior Intensive Care Consultant at Epworth HealthCare (Richmond and Freemasons). She is on the boards of the Digital Health CRC, St Vincent's Institute of Medical Research, FearLess (PTSD-ANZ), and Queen's College (Univ of Melbourne), and the Tuckwell Scholarship Selection Panel at ANU. She also works with national bodies including the Australian Commission on Safety and Quality in Healthcare, AusBiotech, and the National Health and Medical Research Council. Previously, she held positions as the Director of Professional Affairs, CICM, as the Executive Director of Research at Epworth HealthCare, and as the Co-Director of the Intensive Care Unit at Epworth Freemasons. She has led initiatives in the St Vincent's Research Directorate including the establishment of the St Vincent's Research Valet Service, development of the Victorian Clinical Trial Gateway portal, Clinical Trials Business Development model, facilitated research activities of the Research Governance Unit, and built linkages between clinicians/researchers and industry, as well as linkages between clinicians/researchers and community.

Mr Mark Ziirsen Non-Executive Director Sep 2020 Director Bio icon

Mr Mark Ziirsen

Non-Executive Director

Mr Ziirsen is an experienced ASX listed, non-executive director and CFO. He served as non-executive director and chair of Respiri Limited, an eHealth SaaS company supporting respiratory health management, and as non-executive director and chair of the Audit and Risk Committee of Orcoda Limited, a SaaS-based technology company. His executive career includes senior finance leadership roles with ASX listed companies including Cochlear Limited, Aristocrat Leisure Limited, Coca-Cola Amatil Limited and Goodman Fielder Limited. He commenced his career with EY in business advisory, tax and management consulting. Most recently, he was CFO and company secretary for Wiseway Group Limited where he led the company through an IPO, listing on ASX. Immediately prior to that he was CFO of listed medtech company Anteris Technologies Limited and before that, Director of Finance and IT for Asia Pacific at hearing implant maker Cochlear Limited. Mark has experience across multiple industry sectors (medtech/health, technology, consumer) and geographies, having worked in Asia for more than 25 years. He is also appointed chair of the Risk committee of the company.

Mr David Lilja Company Secretary Dec 2019
Dr Julian John Chick Non-Executive Director May 2019 Director Bio icon

Dr Julian John Chick

Non-Executive Director

Dr Chick is an executive with more than 25 years of experience in the biotechnology and medical technology industry as well as five years in investment banking. Dr Chick's previous roles include investment adviser, healthcare analyst for private equity investors, portfolio manager, investment banker and venture capitalist. Dr Chick has advanced a number of technologies from discovery through to market as well as leading capital raisings, M&A transactions, company restructuring, business development and licensing transactions.

Ms Michelle Gallaher Chief Executive Officer Mar 2019
Mr Marat Basyrov Non-Executive Director Mar 2019 Director Bio icon

Mr Marat Basyrov

Non-Executive Director

Mr Basyrov is an experience investor and serial entrepreneur, applying creative and technology-forward data and digital solutions across cross-section of industries. He sits on the board of advisors to Forbes AI. As a Chief Executive Officer of Edway Apps Studio and Intelligent Profit Solutions, Mr Basyrov has a record of building a number of data-driven startup companies including Adevi.io. Mr Basyrov has professional network of directors, investors and collaborators across the globe.

Mr Damon Rasheed Executive Director Feb 2019 Director Bio icon

Mr Damon Rasheed

Executive Director

Mr Rasheed has experience in the Artificial Intelligence space.

Director Transactions

OPL directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
17/06/21 Marat Basyrov Transfer 802,000 $0.19 $152,380 Off-market transfer
17/06/21 Marat Basyrov Transfer 802,000 $0.19 $152,380 Off-market transfer
26/04/21 Julian Chick Buy +150,000 $0.15 $22,500 Participation in share purchase plan
26/04/21 Damon Rasheed Buy +80,400 $0.15 $12,060 Participation in share purchase plan
18/01/21 Damon Rasheed Buy +42,267 $0.165 $6,974 On-market trade
08/09/20 Damon Rasheed Buy +30,000 $0.194 $5,820 On-market trade
23/06/20 Julian Chick Buy +222,222 $0.09 $19,998 On-market trade
03/12/19 Julian Chick Buy +103,274 $0.141 $14,537 On-market trade
15/10/19 Damon Rasheed Buy +4,000,000 $0.002 $8,000 On-market trade
14/10/19 Julian Chick Transfer 4,033,333 $0.002 $8,067 Off-market transfer
14/10/19 Julian Chick Transfer 4,033,333 $0.002 $8,067 Off-market transfer
14/10/19 Julian Chick Buy +9,891,196 $0.002 $19,782 On-market trade
19/07/19 Julian Chick Issued 1,613,333 $0.001 $1,613 Rights issue
11/01/19 Noah Abelson-Gertler Expiry 2,916,666 $0.002 $5,833 Options expired
11/01/19 Lee Rodne Expiry 2,916,666 $0.002 $5,833 Options expired
11/01/19 Noah Abelson-Gertler Expiry 15,000,000 $0.002 $30,000 As advised by the company

Director Interests

The current holdings of OPL directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Marat Basyrov 17/06/2021 0 802,000 129,998 N/A
Megan Robertson 05/05/2021 0 N/A N/A N/A
Damon Rasheed 26/04/2021 192,667 N/A 129,998 N/A
Julian Chick 26/04/2021 0 614,741 184,998 N/A
Mark Ziirsen 21/09/2020 0 N/A N/A N/A

Shareholder Info

Top 20 Shareholders About the Data

Data supplied by Morningstar and accurate on Jul 15, 2020.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Scintilla Strategic Investments Limited 1,877,532 5.09%
Altor Capital Management Pty Ltd (Altor Alpha Fund A/C) 1,011,077 2.74%
Hongkong Frank Pty Ltd (Davis Super Fund A/C) 850,000 2.30%
Rewop Pty Ltd (Scott Power Super Fund A/C) 840,669 2.28%
UBS Nominees Pty Ltd 762,500 2.07%
Mr Marat Basyrov 730,000 1.98%
Kamarel Pty Ltd (K F & M L Smith S/F A/C) 700,000 1.90%
Dr Derek Anthony Jellinek 683,153 1.85%
Cs Third Nominees Pty Limited (Hsbc Cust Nom Au Ltd 13 A/C) 619,400 1.68%
Supertank Pty Ltd (Supertank Superfund A/C) 500,000 1.36%
Noah Abelson 491,188 1.33%
Mr Robert Gareth Price & Mr Steven David Price (Simest Super Fund A/C) 406,150 1.10%
DLK Investments Group Pty Ltd (The DLK Investments Unit A/C) 400,000 1.08%
Dr Thomas Peter Clarke & Mrs Gilda Frances Clarke (Tp&Gf Clarke Super Fund A/C) 400,000 1.08%
Mr Elie Chakkour 400,000 1.08%
Mrs Jacinta May Wilkie 399,250 1.08%
Carter Hosking Pty Ltd (Carter Hosking S/Fund A/C) 380,480 1.03%
Doloc Pty Ltd (The Clive Briggs Psl S/F A/C) 361,711 0.98%
Mr Thomas Robert Sartor 360,400 0.98%
RCKC Nominees Pty Ltd 330,000 0.89%

Shareholder Distribution

As reported in the most recent Annual Report.

The most recent Annual Report didn't contain Shareholder Distribution data.

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Scintilla Strategic Investments Limited 15/07/2020 1,877,532 5.09

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2020 $0.087 30 June
Page Icon
OPL Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.